Core Insights - Aspen Neuroscience has successfully closed a Series C funding round, raising $115 million to advance the clinical development of its lead autologous cell therapy candidate, ANPD001, for moderate-to-advanced Parkinson's disease [1] - The funding will also enhance the company's manufacturing capabilities and support additional therapies in its pipeline [1] Funding Details - The Series C round was co-led by OrbiMed, Frazier Life Sciences, ARCH Venture Partners, and Revelation Partners, with participation from existing investors such as Medical Excellence Capital, Axon Ventures, S32, LifeForce Capital, and LYFE Capital [2] - New investors include Gilead's Kite, Balyasny Asset Management, Cormorant Asset Management, and Prebys Ventures, bringing the total funds raised by Aspen to over $340 million, which includes an $8 million grant from the California Institute for Regenerative Medicine (CIRM) [2] Use of Funds - The funds will be allocated to advancing the company's pipeline of autologous induced pluripotent stem cell (iPSC)-derived therapies targeting additional neurological conditions [3] - Aspen's manufacturing platform utilizes machine learning and genomics to create personalized cells for individual patients [3] Clinical Development Progress - The financing follows the initiation of dosing for the Phase I/IIa Cohort three commercial formulation and the presentation of six-month efficacy and safety data for Cohort one [4] - ANPD001 has received fast-track designation from the US Food and Drug Administration [4] Leadership and Strategic Vision - Aspen Neuroscience's CEO, Damien McDevitt, expressed gratitude for the confidence shown by investors, emphasizing the importance of their experience and capital resources in advancing clinical development and commercial readiness [5] - The strategic guidance and financial support from the investor syndicate will enable Aspen to scale operations, expand its pipeline, and bring transformative therapies closer to patients in need [5]

Core Insights - Aspen Neuroscience, Inc. has successfully closed a $115 million Series C financing round to advance the clinical development of its lead program, ANPD001, aimed at treating moderate to advanced Parkinson's disease [1][2][4] Financing Details - The Series C round was co-led by prominent investors including OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from existing investors and new investors such as Kite, a Gilead Company [2][3] - This funding round brings the total capital raised by Aspen to over $340 million, which includes an $8 million grant from the California Institute for Regenerative Medicine [2] Clinical Development - The financing will support ongoing clinical trials of ANPD001, scale manufacturing capabilities, and advance Aspen's pipeline of autologous iPSC-derived therapies for additional neurological indications [10] - Aspen has initiated dosing for the Phase 1/2a Cohort 3 commercial formulation and has presented promising safety and efficacy data for Cohort 1 at six months post-procedure [6][9] Unique Therapeutic Approach - ANPD001 is the most advanced autologous investigational cell therapy in the U.S. for treating Parkinson's disease, designed to avoid the need for immunosuppressive drugs, thus minimizing associated adverse events [7][8] - The proprietary manufacturing platform utilizes machine learning and advanced genomics to produce high-quality personalized cells, setting a new benchmark for consistency and scalability in cell therapy [5][11] Strategic Vision - The CEO of Aspen emphasized the importance of this financing in accelerating the company's mission to deliver personalized regenerative therapies for Parkinson's disease and highlighted the strategic guidance and financial support from investors as crucial for scaling operations and expanding the pipeline [4][10]